ICM
BXC icon

Invenomic Capital Management’s BlueLinx BXC Stock Holding History

Invenomic Capital Management’s Portfolio BXC Stock Details BXC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-27,000
Closed -$1.97M – 154
2025
Q3 		$1.97M Sell
27,000
-32,956
-55% -$2.6M 0.1% 134
2025
Q2 		$4.46M Buy
59,956
+11,728
+24% +$820K 0.25% 105
2025
Q1 		$3.62M Buy
+48,228
New +$4.48M 0.18% 129

Other funds holding BXC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.05% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JCP
JB Capital Partners Armonk, New York $646M AUM 39.9% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $2.02B AUM 40.6% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Invenomic Capital Management's BXC Position: Q4 2025 in Review

Invenomic Capital Management sold out of BlueLinx (BXC) in Q4 2025, closing a stake of 27,000 shares — an estimated $1.97M sold.

Invenomic Capital Management first reported a position in BXC in Q1 2025 and held it in 3 quarters. The position peaked at $4.46M in Q2 2025. 135 funds tracked by Wall St. Rank hold BXC as of Q4 2025.

  • Invenomic Capital Management reported no remaining BlueLinx position as of Q4 2025 after selling out during the quarter.
  • Invenomic Capital Management sold 27,000 BlueLinx shares in Q4 2025, an estimated $1.97M.
  • Invenomic Capital Management first reported a position in BlueLinx in Q1 2025 and held it in 3 quarters.
  • Invenomic Capital Management's BlueLinx position peaked at $4.46M in Q2 2025.
  • 135 funds tracked by Wall St. Rank held BlueLinx as of Q4 2025.

Based on Invenomic Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.